Topical Nasal Steroids for allergic rhinitis in children. Is one better than the others? A systematic review and network meta-analysis

Background: Allergic rhinitis (AR) is a prevalent chronic condition in children, impacting quality of life (QoL) and exacerbating conditions like asthma. Topical nasal steroids (TNS) are first-line treatments, but comparative efficacy and safety data among different TNS in children remain limited. T...

Full description

Autores:
Osorno-Ortiz, Santiago
Areti-Angeliki, Veroniki
Villatoro-Rodriquez, Silvia
Goldfeder-De-Gracia, Sydney
Mercado-Lara, Maria Fernanda
Yepes-Núñez, Juan J.
Florez Gomez, Ivan D. Florez
Tipo de recurso:
Fecha de publicación:
2025
Institución:
Universidad de Antioquia
Repositorio:
Repositorio UdeA
Idioma:
eng
OAI Identifier:
oai:bibliotecadigital.udea.edu.co:10495/47792
Acceso en línea:
https://hdl.handle.net/10495/47792
Palabra clave:
Rinitis alérgica
Rhinitis, Allergic
Población pediátrica
Esteroides nasales tópicos
https://id.nlm.nih.gov/mesh/D065631
ODS 3: Salud y bienestar. Garantizar una vida sana y promover el bienestar de todos a todas las edades
Rights
embargoedAccess
License
http://creativecommons.org/licenses/by-nc-sa/4.0/
id UDEA2_82eab184e8a21cdbfe0403e50e2c35e1
oai_identifier_str oai:bibliotecadigital.udea.edu.co:10495/47792
network_acronym_str UDEA2
network_name_str Repositorio UdeA
repository_id_str
dc.title.eng.fl_str_mv Topical Nasal Steroids for allergic rhinitis in children. Is one better than the others? A systematic review and network meta-analysis
title Topical Nasal Steroids for allergic rhinitis in children. Is one better than the others? A systematic review and network meta-analysis
spellingShingle Topical Nasal Steroids for allergic rhinitis in children. Is one better than the others? A systematic review and network meta-analysis
Rinitis alérgica
Rhinitis, Allergic
Población pediátrica
Esteroides nasales tópicos
https://id.nlm.nih.gov/mesh/D065631
ODS 3: Salud y bienestar. Garantizar una vida sana y promover el bienestar de todos a todas las edades
title_short Topical Nasal Steroids for allergic rhinitis in children. Is one better than the others? A systematic review and network meta-analysis
title_full Topical Nasal Steroids for allergic rhinitis in children. Is one better than the others? A systematic review and network meta-analysis
title_fullStr Topical Nasal Steroids for allergic rhinitis in children. Is one better than the others? A systematic review and network meta-analysis
title_full_unstemmed Topical Nasal Steroids for allergic rhinitis in children. Is one better than the others? A systematic review and network meta-analysis
title_sort Topical Nasal Steroids for allergic rhinitis in children. Is one better than the others? A systematic review and network meta-analysis
dc.creator.fl_str_mv Osorno-Ortiz, Santiago
Areti-Angeliki, Veroniki
Villatoro-Rodriquez, Silvia
Goldfeder-De-Gracia, Sydney
Mercado-Lara, Maria Fernanda
Yepes-Núñez, Juan J.
Florez Gomez, Ivan D. Florez
dc.contributor.advisor.none.fl_str_mv Florez Gomez, Ivan D. Florez
dc.contributor.author.none.fl_str_mv Osorno-Ortiz, Santiago
Areti-Angeliki, Veroniki
Villatoro-Rodriquez, Silvia
Goldfeder-De-Gracia, Sydney
Mercado-Lara, Maria Fernanda
Yepes-Núñez, Juan J.
Florez Gomez, Ivan D. Florez
dc.contributor.researchgroup.none.fl_str_mv Grupo de investigación en Otorrinolaringología GIORL
dc.contributor.jury.none.fl_str_mv Beltran Puerta, Jessica
Niño Serna, Laura Fernanda
dc.subject.decs.none.fl_str_mv Rinitis alérgica
Rhinitis, Allergic
topic Rinitis alérgica
Rhinitis, Allergic
Población pediátrica
Esteroides nasales tópicos
https://id.nlm.nih.gov/mesh/D065631
ODS 3: Salud y bienestar. Garantizar una vida sana y promover el bienestar de todos a todas las edades
dc.subject.proposal.spa.fl_str_mv Población pediátrica
Esteroides nasales tópicos
dc.subject.meshuri.none.fl_str_mv https://id.nlm.nih.gov/mesh/D065631
dc.subject.ods.none.fl_str_mv ODS 3: Salud y bienestar. Garantizar una vida sana y promover el bienestar de todos a todas las edades
description Background: Allergic rhinitis (AR) is a prevalent chronic condition in children, impacting quality of life (QoL) and exacerbating conditions like asthma. Topical nasal steroids (TNS) are first-line treatments, but comparative efficacy and safety data among different TNS in children remain limited. This study aimed to evaluate the relative efficacy, safety, and impact on growth of various TNS in pediatric AR through a systematic review and network meta-analysis (NMA). Methods: The study included 53 randomized controlled trials (RCTs) involving 12,959 children with moderate-to-severe AR. Outcomes assessed included symptom reduction (primary), QoL, adverse events (AEs), epistaxis, and growth velocity (measured by stadiometry or knemometry). Risk of bias was evaluated using Cochrane ROB2, and evidence certainty was graded using GRADE. Results: - Efficacy: Triamcinolone obtained a symptom scale reduction of -1.62 SMD (95% CI: -2.32, -0.91, and mometasone showed a reduction of -0.90 SMD (95% CI: -1.62, -0.17), both with low certainty in the evidence. Budesonide was not superior to placebo. - Safety: Budesonide had the lowest odds of AEs (OR: 0.51, 95% CI: 0.29, 0.91). Epistaxis risk was similar across all TNS and placebo. - Growth: Mometasone was associated with superior growth velocity versus placebo (MD: 0.61 cm/year, 95% CI: 0.04, 1.18), while triamcinolone showed reduced growth (MD: -0.4 cm/year, 95% CI: -0.74, -0.05). - QoL: Limited data suggested fluticasone propionate and mometasone improved QoL, but evidence was sparse. Conclusions: Second-generation TNS (e.g., fluticasone, mometasone) demonstrated favorable efficacy and safety profiles, with mometasone showing the best performance in growth. First-generation TNS (e.g., triamcinolone) may impair growth. Evidence gaps persist in long-term growth effects and QoL outcomes. The findings support guideline recommendations favoring second-generation TNS but highlight the need for standardized outcome measures and further research in pediatric populations. Keywords: Allergic rhinitis, children, topical nasal steroids, efficacy, safety, growth.
publishDate 2025
dc.date.accessioned.none.fl_str_mv 2025-10-16T17:33:37Z
dc.date.issued.none.fl_str_mv 2025
dc.date.available.none.fl_str_mv 2027-06-10
dc.type.none.fl_str_mv Trabajo de grado - Maestría
dc.type.redcol.none.fl_str_mv http://purl.org/redcol/resource_type/TM
dc.type.content.none.fl_str_mv Text
dc.type.coarversion.none.fl_str_mv http://purl.org/coar/version/c_b1a7d7d4d402bcce
dc.type.driver.none.fl_str_mv info:eu-repo/semantics/masterThesis
dc.type.version.none.fl_str_mv info:eu-repo/semantics/draft
status_str draft
dc.identifier.uri.none.fl_str_mv https://hdl.handle.net/10495/47792
url https://hdl.handle.net/10495/47792
dc.language.iso.none.fl_str_mv eng
language eng
dc.relation.references.none.fl_str_mv 1. Nur Husna SM, Tan HTT, Md Shukri N, Mohd Ashari NS, Wong KK. Allergic Rhinitis: A Clinical and Pathophysiological Overview. Front Med. 7 de abril de 2022;9:874114.
2. Min YG. The Pathophysiology, Diagnosis and Treatment of Allergic Rhinitis. Allergy Asthma Immunol Res. 2010;2(2):65.
3. Bousquet J, van Cauwenberge P, Khaltaev N. Allergic Rhinitis and Its Impact on Asthma. J Allergy Clin Immunol. noviembre de 2001;108(5):S147-334.
4. Asher MI, Montefort S, Björkstén B, Lai CK, Strachan DP, Weiland SK, et al. Worldwide time trends in the prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and eczema in childhood: ISAAC Phases One and Three repeat multicountry cross-sectional surveys. The Lancet. agosto de 2006;368(9537):733-43.
5. Blaiss MS. Allergic rhinitis: Direct and indirect costs. Allergy Asthma Proc. 1 de septiembre de 2010;31(5):375-80.
6. Bousquet J, Khaltaev N, Cruz AA, Denburg J, Fokkens WJ, Togias A, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA2LEN and AllerGen). Allergy Eur J Allergy Clin Immunol. 2008;63(SUPPL. 86):8-160.
7. Lipworth B, Newton J, Ram B, Small I, Schwarze J. An algorithm recommendation for the pharmacological management of allergic rhinitis in the UK: a consensus statement from an expert panel. NPJ Prim Care Respir Med. 23 de enero de 2017;27(1):3.
8. Van Cauwenberge P, Bachert C, Passalacqua G, Bousquet J, Canonica GW, Durham SR, et al. Consensus statement on the treatment of allergic rhinitis. Allergy Eur J Allergy Clin Immunol. 2000;55(2):116-34.
9. Seidman MD, Gurgel RK, Lin SY, Schwartz SR, Baroody FM, Bonner JR, et al. Clinical Practice Guideline: Allergic Rhinitis. Otolaryngol Neck Surg. febrero de 2015;152(1_suppl):S1-43.
10. Derendorf H, Meltzer EO. Molecular and clinical pharmacology of intranasal corticosteroids: clinical and therapeutic implications. Allergy. octubre de 2008;63(10):1292-300.
11. https://www.drugshortagescanada.ca/discontinuance/40965. Discontinuation report APO-FLUNISOLIDE NASAL SPRAY [Internet]. [cited 2025 Jan 6]
12. Al Sayyad JJ, Fedorowicz Z, Alhashimi D, Jamal A. Topical nasal steroids for intermittent and persistent allergic rhinitis in children [Internet]. Cochrane Database Syst Rev. 2007 Jan 24 [cited 2022 Aug 10];(1):CD003163. Available from: https://doi.org/10.1002/14651858.CD003163.pub4
13. Roberts G, Xatzipsalti M, Borrego LM, Custovic A, Halken S, Hellings PW, et al. Paediatric rhinitis: position paper of the European Academy of Allergy and Clinical Immunology. Allergy. agosto de 2013;n/a-n/a.
14. Okubo K, Kurono Y, Ichimura K, Enomoto T, Okamoto Y, Kawauchi H, et al. Japanese guidelines for allergic rhinitis 2020. Allergol Int. julio de 2020;69(3):331-45.
15. Waddell AN, Patel SK, Toma AG, Maw AR. Intranasal steroid sprays in the treatment of rhinitis: is one better than another? J Laryngol Otol. 2003 Nov;117(11):843-5
16. Allen DB. Systemic effects of intranasal steroids: An endocrinologist’s perspective. J Allergy Clin Immunol. 2000;106(4 SUPPL.):S179-90.
17. Florez ID, De La Cruz-Mena JE, Veroniki AA. Network meta-analysis: a powerful tool for clinicians, decision-makers, and methodologists. J Clin Epidemiol. 2024 Dec;176:111537.
18. Osorno Ortiz S, Veroniki AA, Villatoro-Rodriguez S, Goldfeder De Gracia S, Mercado-Lara MF, Yepes-Núñez JJ, et al. Topical Nasal Steroids for Allergic Rhinitis in Children. Is One Better Than the Others? Protocol for a Systematic Review and Network Meta-analysis. F1000Research. 2024 Aug 20;13:944.
19. Shamseer L, Moher D, Clarke M, Ghersi D, Liberati A, Petticrew M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ. 2 de enero de 2015;349(jan02 1):g7647-g7647.
20. Hutton B, Salanti G, Caldwell DM, Chaimani A, Schmid CH, Cameron C, et al. The PRISMA Extension Statement for Reporting of Systematic Reviews Incorporating Network Meta-analyses of Health Care Interventions: Checklist and Explanations. Ann Intern Med. 2 de junio de 2015;162(11):777-84.
21. Brożek JL, Bousquet J, Baena-Cagnani CE, Bonini S, Canonica GW, Casale TB, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines: 2010 Revision. J Allergy Clin Immunol. septiembre de 2010;126(3):466-76.
22. Brożek JL, Bousquet J, Agache I, Agarwal A, Bachert C, Bosnic-Anticevich S, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines—2016 revision. J Allergy Clin Immunol. octubre de 2017;140(4):950-8
23. Juniper EF. Rhinitis management: the patient’s perspective. Clin Exp Allergy J Br Soc Allergy Clin Immunol. 1998;28 Suppl 6(ceb, 8906443):34-8.
24. Higgins J, Thomas J, Chandler J, Cumpston M, Li T, Page M, et al. Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022). Cochrane, 2022. Available from www.training.cochrane.org/handbook.
25. Juniper EF, Howland WC, Roberts NB, Thompson AK, King DR, Math B. Measuring quality of life in children with rhinoconjunctivitis. J ALLERGY CLIN IMMUNOL. 1998;101(2).
26. Juniper EF, Guyatt GH, Dolovich J. Assessment of quality of life in adolescents with allergic rhinoconjunctivitis: Development and testing of a questionnaire for clinical trials. J Allergy Clin Immunol. febrero de 1994;93(2):413-23.
27. Juniper EF, Ståhl E, Doty RL, Simons FER, Allen DB, Howarth PH. Clinical outcomes and adverse effect monitoring in allergic rhinitis. J Allergy Clin Immunol. 2005;115(3 SUPPL.):S390-413.
28. Organización Mundial de la Salud. OMS indicadores de farmacovigilancia: un manual práctico para la evaluación de los sistemas de farmacovigilancia [Internet]. Ginebra: Organización Mundial de la Salud; 2019 [citado 26 de septiembre de 2023]. 78 p. Disponible en: https://iris.who.int/handle/10665/325851
29. Allen DB. Limitations of short-term studies in predicting long-term adverse effects of inhaled corticosteroids. Allergy. marzo de 1999;54(s49):29-34.
30. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 29 de marzo de 2021;n71.
31. Zotero | Your personal research assistant [Internet]. [citado 11 de septiembre de 2023]. Disponible en: https://www.zotero.org/
32. Covidence [Internet]. [citado 2 de noviembre de 2023]. Covidence - Better systematic review management. Disponible en: https://www.covidence.org/
33. WebPlotDigitizer - Extract data from plots, images, and maps [Internet]. [citado 13 de septiembre de 2023]. Disponible en: https://automeris.io/WebPlotDigitizer/
34. Sterne JAC, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 28 de agosto de 2019;l4898.
35. Page MJ, Sterne JAC, Higgins JPT, Egger M. Investigating and dealing with publication bias and other reporting biases in meta‐analyses of health research: A review. Res Synth Methods. marzo de 2021;12(2):248-59.
36. Egger M, Smith GD, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 13 de septiembre de 1997;315(7109):629-34.
37. Cornell JE, Mulrow CD, Localio R, Stack CB, Meibohm AR, Guallar E, et al. Random-Effects Meta-analysis of Inconsistent Effects: A Time for Change. Ann Intern Med. 18 de febrero de 2014;160(4):267-70.
38. Turner RM, Davey J, Clarke MJ, Thompson SG, Higgins JP. Predicting the extent of heterogeneity in meta-analysis, using empirical data from the Cochrane Database of Systematic Reviews. Int J Epidemiol. junio de 2012;41(3):818-27.
39. Rhodes KM, Turner RM, Higgins JPT. Predictive distributions were developed for the extent of heterogeneity in meta-analyses of continuous outcome data. J Clin Epidemiol. enero de 2015;68(1):52-60.
40. Salanti G. Indirect and mixed-treatment comparison, network, or multiple-treatments meta-analysis: many names, many benefits, many concerns for the next generation evidence synthesis tool. Res Synth Methods. junio de 2012;3(2):80-97.
41. Mills EJ, Thorlund K, Ioannidis JPA. Demystifying trial networks and network meta-analysis. BMJ. 14 de mayo de 2013;346(may14 2):f2914-f2914.
42. Veroniki AA, Straus SE, Fyraridis A, Tricco AC. The rank-heat plot is a novel way to present the results from a network meta-analysis including multiple outcomes. J Clin Epidemiol. agosto de 2016;76:193-9.
43. Veroniki AA, Vasiliadis HS, Higgins JP, Salanti G. Evaluation of inconsistency in networks of interventions. Int J Epidemiol. 1 de febrero de 2013;42(1):332-45.
44. Jackson D, Barrett JK, Rice S, White IR, Higgins JPT. A design‐by‐treatment interaction model for network meta‐analysis with random inconsistency effects. Stat Med. 20 de septiembre de 2014;33(21):3639-54.
45. Veroniki AA, Jackson D, Viechtbauer W, Bender R, Bowden J, Knapp G, et al. Methods to estimate the between‐study variance and its uncertainty in meta‐analysis. Res Synth Methods. marzo de 2016;7(1):55-79.
46. Balduzzi S, Rücker G, Nikolakopoulou A, Papakonstantinou T, Salanti G, Efthimiou O, et al. netmeta : An R Package for Network Meta-Analysis Using Frequentist Methods. J Stat Softw [Internet]. 2023 [citado 9 de diciembre de 2023];106(2). Disponible en: https://www.jstatsoft.org/v106/i02/
47. Allen DB. Do intranasal corticosteroids affect childhood growth? Allergy Eur J Allergy Clin Immunol Suppl. 2000;55(62):15-8.
48. Li AR, Zhang K, Reddy PD, Nguyen SA, Miglani A, Fried J, et al. Systematic review of measures of disease severity in rhinitis. Int Forum Allergy Rhinol. septiembre de 2021;11(9):1367-77.
49. Schandelmaier S, Briel M, Varadhan R, Schmid CH, Devasenapathy N, Hayward RA, et al. Development of the Instrument to assess the Credibility of Effect Modification Analyses (ICEMAN) in randomized controlled trials and meta-analyses. Can Med Assoc J. 10 de agosto de 2020;192(32):E901-6.
50. Puhan MA, Schunemann HJ, Murad MH, Li T, Brignardello-Petersen R, Singh JA, et al. A GRADE Working Group approach for rating the quality of treatment effect estimates from network meta-analysis. BMJ. 24 de septiembre de 2014;349(sep24 5):g5630-g5630.
51. Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J, et al. GRADE guidelines: 1. Introduction—GRADE evidence profiles and summary of findings tables. J Clin Epidemiol. abril de 2011;64(4):383-94.
52. Guyatt GH, Oxman AD, Kunz R, Woodcock J, Brozek J, Helfand M, et al. GRADE guidelines: 7. Rating the quality of evidence—inconsistency. J Clin Epidemiol. diciembre de 2011;64(12):1294-302.
53. Guyatt GH, Oxman AD, Kunz R, Brozek J, Alonso-Coello P, Rind D, et al. GRADE guidelines 6. Rating the quality of evidence—imprecision. J Clin Epidemiol. diciembre de 2011;64(12):1283-93.
54. Guyatt GH, Oxman AD, Montori V, Vist G, Kunz R, Brozek J, et al. GRADE guidelines: 5. Rating the quality of evidence—publication bias. J Clin Epidemiol. diciembre de 2011;64(12):1277-82.
55. Dias S, Welton NJ, Caldwell DM, Ades AE. Checking consistency in mixed treatment comparison meta‐analysis. Stat Med. 30 de marzo de 2010;29(7-8):932-44.
56. Brignardello-Petersen R, Florez ID, Izcovich A, Santesso N, Hazlewood G, Alhazanni W, et al. GRADE approach to drawing conclusions from a network meta-analysis using a minimally contextualised framework. BMJ. 11 de noviembre de 2020;m3900.
57. Berger WE, Nayak A, Lanier BQ, Kaiser HB, LaForce C, Darken P, et al. Efficacy and safety of once-daily ciclesonide nasal spray in children with allergic rhinitis. Pediatr Asthma Allergy Immunol. 2008;21(2):73.
58. Mak KK, Ku MS, Lu KH, Sun HL, Lue KH. Comparison of mometasone furoate monohydrate (Nasonex) and fluticasone propionate (Flixonase) nasal sprays in the treatment of dust mite-sensitive children with perennial allergic rhinitis. Pediatr Neonatol. 2013;54(4):239-45.
59. Indolfi C, Dinardo G, Umano GR, Klain A, Contieri M, Decimo A, et al. Mometasone furoate nasal spray in Italian children with seasonal allergic rhinitis: a comprehensive assessment. Allergol Immunopathol (Madr). 2022;50(5):61-7.
60. Zicari AM, Occasi F, Montanari G, Indinnimeo L, De Castro G, Tancredi G, et al. Intranasal budesonide in children affected by persistent allergic rhinitis and its effect on nasal patency and Nasal Obstruction Symptom Evaluation (NOSE) score. Curr Med Res Opin. 2015;31(3):391.
61. Gale AE, Solomon E, Tao BS. Intranasal topical flunisolide therapy in children with seasonal allergic rhinitis. Clin Allergy. 1980;10(5):527.
62. Lee LA, Sterling R, Maspero J, Clements D, Ellsworth A, Pedersen S. Growth velocity reduced with once-daily fluticasone furoate nasal spray in prepubescent children with perennial allergic rhinitis. J Allergy Clin Immunol Pract. 2014;2(4):421-7.
63. Okubo K, Okamasa A, Honma G, Komatsubara M. Safety and efficacy of fluticasone furoate nasal spray in Japanese children 2 to <15 years of age with perennial allergic rhinitis: a multicentre, open-label trial. Allergol Int Off J Jpn Soc Allergol. 2015;64(1):60-5.
64. Tripathy I, Levy A, Ratner P, Clements D, Wu W, Philpot E. HPA axis safety of fluticasone furoate nasal spray once daily in children with perennial allergic rhinitis. Pediatr Allergy Immunol Off Publ Eur Soc Pediatr Allergy Immunol. 2009;20(3):287-94.
65. GlaxoSmithKline. Study FFR116364, a Double-blind, Placebo-controlled Study of GW685698X in Paediatric Subjects With Perennial Allergic Rhinitis [Internet]. clinicaltrials.gov; 2016. Disponible en: https://clinicaltrials.gov/study/NCT01630135
66. Meltzer EO, Lee J, Tripathy I, Lim J, Ellsworth, A, et al. Efficacy and safety of once-daily fluticasone furoate nasal spray in children with seasonal allergic rhinitis treated for 2 wk. Pediatr Allergy Immunol. 2008;
67. Maspero JF, Rosenblut A, Finn AJ, Lim J, Wu W, Philpot E. Safety and efficacy of fluticasone furoate in pediatric patients with perennial allergic rhinitis. Otolaryngol--Head Neck Surg Off J Am Acad Otolaryngol-Head Neck Surg. 2008;138(1):30-7.
68. Banov CH, Silvers WS, Green AW, van Bavel JH, Winder JA, Feiss G, et al. Placebo-controlled, double-blind study of the efficacy and safety of triamcinolone acetonide aerosol nasal inhaler in pediatric patients with seasonal allergic rhinitis. Clin Ther. 1996;18(2):265.
69. Storms WW, Southern DL, Feiss G, Simpson B, Furst JA, Smith JA. Efficacy of triamcinolone acetonide aerosol nasal inhaler in children with perennial allergic rhinitis. Pediatr Asthma Allergy Immunol. 1996;10(2):59.
70. Schenkel EJ, Gross G, Jacobson K, Kobayashi R, Settipane G, Savacool AM, et al. Triamcinolone acetonide aqueous nasal inhaler for the treatment of spring grass seasonal allergic rhinitis in children. Pediatr Asthma Allergy Immunol. 1997;11(2):129.
71. Weinstein S, Qaqundah P, Georges G, Nayak A. Efficacy and safety of triamcinolone acetonide aqueous nasal spray in children aged 2 to 5 years with perennial allergic rhinitis: a randomized, double-blind, placebo-controlled study with an open-label extension. Ann Allergy Asthma Immunol. 2009;102(4):339.
72. Sanofi. A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study Evaluating the Pharmacodynamic Effect of a 6-week Treatment With Triamcinolone Acetonide Aqueous Nasal Spray 110 μg and 220 μg Once Daily on Basal Hypothalamic-Pituitary-Adrenal (HPA) Axis Function in Children [>=2 to < 12 Years of Age] With Allergic Rhinitis (AR). [Internet]. clinicaltrials.gov; 2012 jun [citado 31 de diciembre de 2022]. Report No.: NCT01154153. Disponible en: https://clinicaltrials.gov/study/NCT01154153
73. Agertoft L, Wolthers OD, Fuglsang G, Pedersen S. Nasal powder administration of budesonide for seasonal rhinitis in children and adolescents. Pediatr Allergy Immunol Off Publ Eur Soc Pediatr Allergy Immunol. 1993;4(3):152-6.
74. Ferrante G, Fasola S, Cilluffo G, Malizia V, Montalbano L, Landi M, et al. Nasal budesonide efficacy for nasal nitric oxide and nasal obstruction in rhinitis. Pediatr Allergy Immunol. 2017;28(4):393-7.
75. Fokkens WJ, Cserhati E, dos Santos JML, Praca F, van Zanten M, Schade A, et al. Budesonide aqueous nasal spray is an effective treatment in children with perennial allergic rhinitis, with an onset of action within 12 hours. Ann Allergy Asthma Immunol Off Publ Am Coll Allergy Asthma Immunol. 2002;89(3):279-84.
76. Ngamphaiboon J, Thepchatri A, Chatchatee P, Chumdermpadetsuk S. Fluticasone propionate aqueous nasal spray treatment for perennial allergic rhinitis in children. Ann Allergy Asthma Immunol Off Publ Am Coll Allergy Asthma Immunol. 1997;78(5):479-84.
77. Fluticasone P Collab Work Group. Treatment of seasonal allergic rhinitis with once-daily intranasal fluticasone propionate therapy in children. Fluticasone Propionate Collaborative Pediatric Working Group. J Pediatr. 1994;125(4):628-34.
78. Grossman J, Banov C, Bronsky EA, Nathan RA, Pearlman D, Winder JA, et al. Fluticasone propionate aqueous nasal spray is safe and effective for children with seasonal allergic rhinitis. Pediatrics. 1993;92(4):594-9.
79. Munk ZM, Pearlman D, Graft D, Green A, Hampel F, Pleskow W, et al. Intranasal fluticasone propionate is effective and well-tolerated in adolescents with seasonal allergic rhinitis. Pediatr Asthma Allergy Immunol. 1994;8(1):39.
80. Baena-Cagnani CE, Patel P. Efficacy and long-term safety of mometasone furoate nasal spray in children with perennial allergic rhinitis. Curr Med Res Opin. 2010;26(9):2047.
81. Organon and Co. Multicenter, Double-blind, Randomized, Placebo-controlled Study of Mometasone Furoate Nasal Spray in Pediatric Subjects With Perennial Allergic Rhinitis (Protocol No.P06332) [Internet]. clinicaltrials.gov; 2024 may [citado 8 de diciembre de 2024]. Report No.: NCT01135134. Disponible en: https://clinicaltrials.gov/study/NCT01135134
82. Berger WE, Jacobs RL, Amar NJ, Tantry SK, Li J, Small CJ. Efficacy and safety of beclomethasone dipropionate nasal aerosol in children with perennial allergic rhinitis. Ann Allergy Asthma Immunol. 2015;115(2):130-6.
83. Lin MT, Collins-Williams C. Intranasal beclomethasone dipropionate for perennial allergic rhinitis. Can Med Assoc J. 1977;116(8):895-6.
84. Sarsfield JK, Thomson GE. Flunisolide nasal spray for perennial rhinitis in children. Br Med J. 1979;2(6182):95-7.
85. Meltzer EO, Berger WE, Berkowitz RB, Bronsky EA, Dvorin DJ, Finn AF, et al. A dose-ranging study of mometasone furoate aqueous nasal spray in children with seasonal allergic rhinitis. J Allergy Clin Immunol. 1999;104(1):107.
86. Organon and Co. Dose-Ranging Study of Mometasone Furoate Nasal Spray (SCH 32088) in the Treatment of Children (Ages 6-11) With Seasonal Allergic Rhinitis (Protocol C95-161) [Internet]. clinicaltrials.gov; 2022. Disponible en: https://clinicaltrials.gov/study/NCT03879772
87. Sumitomo Pharma America Inc. A 12-Week Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Safety and Efficacy Study of Ciclesonide Nasal Aerosol in Subjects 6-11 Years With Perennial Allergic Rhinitis [Internet]. clinicaltrials.gov; 2014. Disponible en: https://clinicaltrials.gov/study/NCT01451541
88. Skoner DP, Gentile D, Angelini B, Kane R, Birdsall D, Banerji D. The effects of intranasal triamcinolone acetonide and intranasal fluticasone propionate on short-term bone growth and HPA axis in children with allergic rhinitis. Ann Allergy Asthma Immunol. 2003;90(1):56.
89. Sanofi. A Randomized, Multicenter, Double-blind, Placebo-controlled, Parallel Group Study of the 12 Month Effect of Treatment With Once Daily Triamcinolone Acetonide (NASACORT® AQ Nasal Spray 110 μg) on the Growth Velocity of Children, 3 to 9 Years of Age, With Perennial Allergic Rhinitis (PAR) [Internet]. clinicaltrials.gov; 2012 ago [citado 31 de diciembre de 2022]. Report No.: NCT00449072. Disponible en: https://clinicaltrials.gov/study/NCT00449072
90. Georges G, Kim KT, Ratner P, Segall N, Qiu C. Effect of intranasal triamcinolone acetonide on basal hypothalamic-pituitary-adrenal axis function in children with allergic rhinitis. Allergy Asthma Proc. 2014;35(2):163-70.
91. EudraCT Number 2014-004645-27 - Clinical trial results - EU Clinical Trials Register [Internet]. [citado 10 de diciembre de 2024]. Disponible en: https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-004645-27/results
92. Boner AL, Sette L. Rhinitis in children: efficacy and safety of a new intranasal corticosteroid. Eur Respir Rev. 1994;4(20):271.
93. Galant SP, Melamed IR, Nayak AS, Blake KV, Prillaman BA, Reed KD, et al. Lack of effect of fluticasone propionate aqueous nasal spray on the hypothalamic-pituitary-adrenal axis in 2- and 3-year-old patients. Pediatrics. 2003;112(1 Pt 1):96-100.
94. Allen DB, Meltzer EO, Lemanske RF, Philpot EE, Faris MA, Kral KM, et al. No growth suppression in children treated with the maximum recommended dose of fluticasone propionate aqueous nasal spray for one year. Allergy Asthma Proc. 2002;23(6):407.
95. Hampel FC, Nayak NA, Segall N, Small CJ, Li J, Tantry SK. No hypothalamic-pituitary-adrenal function effect with beclomethasone dipropionate nasal aerosol, based on 24-hour serum cortisol in pediatric allergic rhinitis. Ann Allergy Asthma Immunol. 2015;115(2):137-42.
96. Skoner DP, Rachelefsky GS, Meltzer EO, Chervinsky P, Morris RM, Seltzer JM, et al. Detection of growth suppression in children during treatment with intranasal beclomethasone dipropionate. Pediatrics. 2000;105(2):E23.
97. Storms WW, Segall N, Mansfield LE, Amar NJ, Kelley L, Ding Y, et al. Efficacy and safety of beclomethasone dipropionate nasal aerosol in pediatric patients with seasonal allergic rhinitis. Ann Allergy Asthma Immunol. 2013;111(5):408-414.e1.
98. Berger WE, Jacobs RL, Amar NJ, Tantry SK, Li J, Small CJ. Efficacy and safety of beclomethasone dipropionate nasal aerosol in children with perennial allergic rhinitis. Ann Allergy Asthma Immunol Off Publ Am Coll Allergy Asthma Immunol. agosto de 2015;115(2):130-6.
99. Organon and Co. Efficacy and Safety of Mometasone Furoate Aqueous Nasal Spray vs Placebo and Flonase® (Fluticasone Propionate) in Seasonal Allergic Rhinitis Patients (I94-001) [Internet]. clinicaltrials.gov; 2022 feb [citado 31 de diciembre de 2022]. Report No.: NCT03882047. Disponible en: https://clinicaltrials.gov/study/NCT03882047
100. Kim KT, Rabinovitch N, Uryniak T, Simpson B, O’Dowd L, Casty F. Effect of budesonide aqueous nasal spray on hypothalamic-pituitary-adrenal axis function in children with allergic rhinitis. Ann Allergy Asthma Immunol Off Publ Am Coll Allergy Asthma Immunol. 2004;93(1):61-7.
101. Murphy K, Uryniak T, Simpson B, O’Dowd L. Growth velocity in children with perennial allergic rhinitis treated with budesonide aqueous nasal spray. Ann Allergy Asthma Immunol Off Publ Am Coll Allergy Asthma Immunol. 2006;96(5):723-30.
102. Agertoft L, Pedersen S. Short-term lower leg growth rate in children with rhinitis treated with intranasal mometasone furoate and budesonide. J Allergy Clin Immunol. 1999;104(5):948.
103. Wolthers OD, Jørgensen BA, Pedersen S. A double-blind, placebo-controlled study of the effect of intranasal budesonide in the treatment of children with seasonal rhinitis. Acta Paediatr. noviembre de 1992;81(11):902-6.
104. Okubo K, Okamasa A, Honma G, Komatsubara M. Efficacy and safety of fluticasone furoate nasal spray in Japanese children with perennial allergic rhinitis: a multicentre, randomized, double-blind, placebo-controlled trial. Allergol Int Off J Jpn Soc Allergol. 2014;63(4):543-51.
105. Maspero JF, Rosenblut A, Finn A Jr, Lim J, Wu W, Faris M, et al. Once daily fluticasone furoate nasal spray (FF) is safe and effective in long term treatment of perennial allergic rhinitis (PAR) in children ages 2 to 11 years USAN approved name. J Allergy Clin Immunol. 2007;119(1 Suppl):S304.
106. Zhang Y, Wei P, Chen B, Li X, Luo X, Chen X, et al. Intranasal fluticasone furoate in pediatric allergic rhinitis: randomized controlled study. Pediatr Res. 2021;89(7):1832.
107. Cutler DL, Banfield C, Affrime MB. Safety of mometasone furoate nasal spray in children with allergic rhinitis as young as 2 years of age: a randomized controlled trial. Pediatr Asthma Allergy Immunol. 2006;19(3):146.
108. Schenkel EJ, Skoner DP, Bronsky EA, Miller SD, Pearlman DS, Rooklin A, et al. Absence of growth retardation in children with perennial allergic rhinitis after one year of treatment with mometasone furoate aqueous nasal spray. Pediatrics. 2000;105(2):E22.
109. Meltzer EO, Berger WE, Berkowitz RB, Bronsky EA, Dvorin DJ, Finn AF, et al. A dose-ranging study of mometasone furoate aqueous nasal spray in children with seasonal allergic rhinitis. J Allergy Clin Immunol. 1999;104(1):107.
110. Ratner PH, Meltzer EO, Teper A. Mometasone furoate nasal spray is safe and effective for 1-year treatment of children with perennial allergic rhinitis. Int J Pediatr Otorhinolaryngol. 2009;73(5):651-7.
111. Skoner DP, Berger WE, Gawchik SM, Akbary A, Qiu C. Intranasal triamcinolone and growth velocity. Pediatrics. 2015;135(2):e348.
112. Agertoft L, Pedersen S. Short-term lower leg growth rate in children with rhinitis treated with intranasal mometasone furoate and budesonide. J Allergy Clin Immunol. 1999;104(5):948.
113. Wolthers OD, Pedersen S. Knemometric assessment of systemic activity of once daily intranasal dry-powder budesonide in children. 1994;49(2):96.
114. Gradman J, Caldwell MF, Wolthers OD. A 2-week, crossover study to investigate the effect of fluticasone furoate nasal spray on short-term growth in children with allergic rhinitis. Clin Ther. 2007;29(8):1738-47.
115. Barnes ML, Vaidyanathan S, Williamson PA, Lipworth BJ. The minimal clinically important difference in allergic rhinitis. Clin Exp Allergy. febrero de 2010;40(2):242-50.
116. Cohen J. The earth is round (p < .05). APA PsycArticles J Artic. 1994;49(12):997-1003.
117. Kırıs M, Muderris T, Celebi S, Cankaya H, Bercin S. Changes in serum IGF-1 and IGFBP-3 levels and growth in children following adenoidectomy, tonsillectomy or adenotonsillectomy. Int J Pediatr Otorhinolaryngol. mayo de 2010;74(5):528-31.
118. Li Y, Xiong J, Zhang Z, Liao K, Zhou X, Li J, et al. Efficacy and safety of various corticosteroids in the treatment of children with allergic rhinitis: A systematic review and network meta‐analysis. J Evid-Based Med. septiembre de 2024;17(3):626-42.
119. Sousa‐Pinto B, Vieira RJ, Bognanni A, Gil‐Mata S, Ferreira‐da‐Silva R, Ferreira A, et al. Efficacy and safety of intranasal medications for allergic rhinitis: Network meta‐analysis. Allergy. 16 de noviembre de 2024;all.16384.
120. Lei R, Shen Q, Yang B, Hou T, Liu H, Luo X, et al. Core Outcome Sets in Child Health: A Systematic Review. JAMA Pediatr. 1 de noviembre de 2022;176(11):1131
dc.rights.uri.none.fl_str_mv http://creativecommons.org/licenses/by-nc-sa/4.0/
dc.rights.accessrights.none.fl_str_mv info:eu-repo/semantics/embargoedAccess
dc.rights.license.en.fl_str_mv Attribution-NonCommercial-ShareAlike 4.0 International
dc.rights.coar.none.fl_str_mv http://purl.org/coar/access_right/c_f1cf
rights_invalid_str_mv http://creativecommons.org/licenses/by-nc-sa/4.0/
Attribution-NonCommercial-ShareAlike 4.0 International
http://purl.org/coar/access_right/c_f1cf
eu_rights_str_mv embargoedAccess
dc.format.extent.none.fl_str_mv 25 páginas
dc.format.mimetype.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Universidad de Antioquia
dc.publisher.program.none.fl_str_mv Maestría en Epidemiología Clínica
dc.publisher.department.none.fl_str_mv Departamento de Educación Médica
dc.publisher.place.none.fl_str_mv Medellín, Colombia
dc.publisher.faculty.none.fl_str_mv Facultad de Medicina
dc.publisher.branch.none.fl_str_mv Campus en el Área de la salud
publisher.none.fl_str_mv Universidad de Antioquia
institution Universidad de Antioquia
bitstream.url.fl_str_mv https://bibliotecadigital.udea.edu.co/bitstreams/d69baa8d-8bd3-405f-9db9-1a4eeb43bd4e/download
https://bibliotecadigital.udea.edu.co/bitstreams/cafcc0b0-c894-4bde-ac9c-cf98a8c292c1/download
https://bibliotecadigital.udea.edu.co/bitstreams/8f39dbbe-f3de-4dfc-984c-f47aeaaef26a/download
https://bibliotecadigital.udea.edu.co/bitstreams/2fe6045f-d32e-4eae-a7bf-b5521d18c169/download
https://bibliotecadigital.udea.edu.co/bitstreams/36ca478d-e523-41b0-bef6-475b4812d10b/download
https://bibliotecadigital.udea.edu.co/bitstreams/9b67e894-4c7e-45e1-a4f9-b10759ca1fe4/download
https://bibliotecadigital.udea.edu.co/bitstreams/0f7a1fa9-58e9-4173-b273-a9d2eaaa6602/download
bitstream.checksum.fl_str_mv 7e906757aab883ed3b6c8f5d8a3112f8
943840d5e8d6889d208ac236bea1b48e
b76e7a76e24cf2f94b3ce0ae5ed275d0
5643bfd9bcf29d560eeec56d584edaa9
d32dae1c90884c476680de7b1bc8cfa5
facfa2b28665af6fdd2a661db99edffe
12dffd27729aa62fe1d1ca865c7ce208
bitstream.checksumAlgorithm.fl_str_mv MD5
MD5
MD5
MD5
MD5
MD5
MD5
repository.name.fl_str_mv Repositorio Institucional de la Universidad de Antioquia
repository.mail.fl_str_mv aplicacionbibliotecadigitalbiblioteca@udea.edu.co
_version_ 1851052189521281024
spelling Florez Gomez, Ivan D. FlorezOsorno-Ortiz, SantiagoAreti-Angeliki, VeronikiVillatoro-Rodriquez, SilviaGoldfeder-De-Gracia, SydneyMercado-Lara, Maria FernandaYepes-Núñez, Juan J.Florez Gomez, Ivan D. FlorezGrupo de investigación en Otorrinolaringología GIORLBeltran Puerta, JessicaNiño Serna, Laura Fernanda2025-10-16T17:33:37Z2027-06-102025https://hdl.handle.net/10495/47792Background: Allergic rhinitis (AR) is a prevalent chronic condition in children, impacting quality of life (QoL) and exacerbating conditions like asthma. Topical nasal steroids (TNS) are first-line treatments, but comparative efficacy and safety data among different TNS in children remain limited. This study aimed to evaluate the relative efficacy, safety, and impact on growth of various TNS in pediatric AR through a systematic review and network meta-analysis (NMA). Methods: The study included 53 randomized controlled trials (RCTs) involving 12,959 children with moderate-to-severe AR. Outcomes assessed included symptom reduction (primary), QoL, adverse events (AEs), epistaxis, and growth velocity (measured by stadiometry or knemometry). Risk of bias was evaluated using Cochrane ROB2, and evidence certainty was graded using GRADE. Results: - Efficacy: Triamcinolone obtained a symptom scale reduction of -1.62 SMD (95% CI: -2.32, -0.91, and mometasone showed a reduction of -0.90 SMD (95% CI: -1.62, -0.17), both with low certainty in the evidence. Budesonide was not superior to placebo. - Safety: Budesonide had the lowest odds of AEs (OR: 0.51, 95% CI: 0.29, 0.91). Epistaxis risk was similar across all TNS and placebo. - Growth: Mometasone was associated with superior growth velocity versus placebo (MD: 0.61 cm/year, 95% CI: 0.04, 1.18), while triamcinolone showed reduced growth (MD: -0.4 cm/year, 95% CI: -0.74, -0.05). - QoL: Limited data suggested fluticasone propionate and mometasone improved QoL, but evidence was sparse. Conclusions: Second-generation TNS (e.g., fluticasone, mometasone) demonstrated favorable efficacy and safety profiles, with mometasone showing the best performance in growth. First-generation TNS (e.g., triamcinolone) may impair growth. Evidence gaps persist in long-term growth effects and QoL outcomes. The findings support guideline recommendations favoring second-generation TNS but highlight the need for standardized outcome measures and further research in pediatric populations. Keywords: Allergic rhinitis, children, topical nasal steroids, efficacy, safety, growth.COL0211869MaestríaMagíster en Epidemiología Clínica25 páginasapplication/pdfengUniversidad de AntioquiaMaestría en Epidemiología ClínicaDepartamento de Educación MédicaMedellín, ColombiaFacultad de MedicinaCampus en el Área de la saludhttp://creativecommons.org/licenses/by-nc-sa/4.0/info:eu-repo/semantics/embargoedAccessAttribution-NonCommercial-ShareAlike 4.0 Internationalhttp://purl.org/coar/access_right/c_f1cfTopical Nasal Steroids for allergic rhinitis in children. Is one better than the others? A systematic review and network meta-analysisTrabajo de grado - Maestríahttp://purl.org/redcol/resource_type/TMTexthttp://purl.org/coar/version/c_b1a7d7d4d402bcceinfo:eu-repo/semantics/masterThesisinfo:eu-repo/semantics/draft1. Nur Husna SM, Tan HTT, Md Shukri N, Mohd Ashari NS, Wong KK. Allergic Rhinitis: A Clinical and Pathophysiological Overview. Front Med. 7 de abril de 2022;9:874114.2. Min YG. The Pathophysiology, Diagnosis and Treatment of Allergic Rhinitis. Allergy Asthma Immunol Res. 2010;2(2):65.3. Bousquet J, van Cauwenberge P, Khaltaev N. Allergic Rhinitis and Its Impact on Asthma. J Allergy Clin Immunol. noviembre de 2001;108(5):S147-334.4. Asher MI, Montefort S, Björkstén B, Lai CK, Strachan DP, Weiland SK, et al. Worldwide time trends in the prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and eczema in childhood: ISAAC Phases One and Three repeat multicountry cross-sectional surveys. The Lancet. agosto de 2006;368(9537):733-43.5. Blaiss MS. Allergic rhinitis: Direct and indirect costs. Allergy Asthma Proc. 1 de septiembre de 2010;31(5):375-80.6. Bousquet J, Khaltaev N, Cruz AA, Denburg J, Fokkens WJ, Togias A, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA2LEN and AllerGen). Allergy Eur J Allergy Clin Immunol. 2008;63(SUPPL. 86):8-160.7. Lipworth B, Newton J, Ram B, Small I, Schwarze J. An algorithm recommendation for the pharmacological management of allergic rhinitis in the UK: a consensus statement from an expert panel. NPJ Prim Care Respir Med. 23 de enero de 2017;27(1):3.8. Van Cauwenberge P, Bachert C, Passalacqua G, Bousquet J, Canonica GW, Durham SR, et al. Consensus statement on the treatment of allergic rhinitis. Allergy Eur J Allergy Clin Immunol. 2000;55(2):116-34.9. Seidman MD, Gurgel RK, Lin SY, Schwartz SR, Baroody FM, Bonner JR, et al. Clinical Practice Guideline: Allergic Rhinitis. Otolaryngol Neck Surg. febrero de 2015;152(1_suppl):S1-43.10. Derendorf H, Meltzer EO. Molecular and clinical pharmacology of intranasal corticosteroids: clinical and therapeutic implications. Allergy. octubre de 2008;63(10):1292-300.11. https://www.drugshortagescanada.ca/discontinuance/40965. Discontinuation report APO-FLUNISOLIDE NASAL SPRAY [Internet]. [cited 2025 Jan 6]12. Al Sayyad JJ, Fedorowicz Z, Alhashimi D, Jamal A. Topical nasal steroids for intermittent and persistent allergic rhinitis in children [Internet]. Cochrane Database Syst Rev. 2007 Jan 24 [cited 2022 Aug 10];(1):CD003163. Available from: https://doi.org/10.1002/14651858.CD003163.pub413. Roberts G, Xatzipsalti M, Borrego LM, Custovic A, Halken S, Hellings PW, et al. Paediatric rhinitis: position paper of the European Academy of Allergy and Clinical Immunology. Allergy. agosto de 2013;n/a-n/a.14. Okubo K, Kurono Y, Ichimura K, Enomoto T, Okamoto Y, Kawauchi H, et al. Japanese guidelines for allergic rhinitis 2020. Allergol Int. julio de 2020;69(3):331-45.15. Waddell AN, Patel SK, Toma AG, Maw AR. Intranasal steroid sprays in the treatment of rhinitis: is one better than another? J Laryngol Otol. 2003 Nov;117(11):843-516. Allen DB. Systemic effects of intranasal steroids: An endocrinologist’s perspective. J Allergy Clin Immunol. 2000;106(4 SUPPL.):S179-90.17. Florez ID, De La Cruz-Mena JE, Veroniki AA. Network meta-analysis: a powerful tool for clinicians, decision-makers, and methodologists. J Clin Epidemiol. 2024 Dec;176:111537.18. Osorno Ortiz S, Veroniki AA, Villatoro-Rodriguez S, Goldfeder De Gracia S, Mercado-Lara MF, Yepes-Núñez JJ, et al. Topical Nasal Steroids for Allergic Rhinitis in Children. Is One Better Than the Others? Protocol for a Systematic Review and Network Meta-analysis. F1000Research. 2024 Aug 20;13:944.19. Shamseer L, Moher D, Clarke M, Ghersi D, Liberati A, Petticrew M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ. 2 de enero de 2015;349(jan02 1):g7647-g7647.20. Hutton B, Salanti G, Caldwell DM, Chaimani A, Schmid CH, Cameron C, et al. The PRISMA Extension Statement for Reporting of Systematic Reviews Incorporating Network Meta-analyses of Health Care Interventions: Checklist and Explanations. Ann Intern Med. 2 de junio de 2015;162(11):777-84.21. Brożek JL, Bousquet J, Baena-Cagnani CE, Bonini S, Canonica GW, Casale TB, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines: 2010 Revision. J Allergy Clin Immunol. septiembre de 2010;126(3):466-76.22. Brożek JL, Bousquet J, Agache I, Agarwal A, Bachert C, Bosnic-Anticevich S, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines—2016 revision. J Allergy Clin Immunol. octubre de 2017;140(4):950-823. Juniper EF. Rhinitis management: the patient’s perspective. Clin Exp Allergy J Br Soc Allergy Clin Immunol. 1998;28 Suppl 6(ceb, 8906443):34-8.24. Higgins J, Thomas J, Chandler J, Cumpston M, Li T, Page M, et al. Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022). Cochrane, 2022. Available from www.training.cochrane.org/handbook.25. Juniper EF, Howland WC, Roberts NB, Thompson AK, King DR, Math B. Measuring quality of life in children with rhinoconjunctivitis. J ALLERGY CLIN IMMUNOL. 1998;101(2).26. Juniper EF, Guyatt GH, Dolovich J. Assessment of quality of life in adolescents with allergic rhinoconjunctivitis: Development and testing of a questionnaire for clinical trials. J Allergy Clin Immunol. febrero de 1994;93(2):413-23.27. Juniper EF, Ståhl E, Doty RL, Simons FER, Allen DB, Howarth PH. Clinical outcomes and adverse effect monitoring in allergic rhinitis. J Allergy Clin Immunol. 2005;115(3 SUPPL.):S390-413.28. Organización Mundial de la Salud. OMS indicadores de farmacovigilancia: un manual práctico para la evaluación de los sistemas de farmacovigilancia [Internet]. Ginebra: Organización Mundial de la Salud; 2019 [citado 26 de septiembre de 2023]. 78 p. Disponible en: https://iris.who.int/handle/10665/32585129. Allen DB. Limitations of short-term studies in predicting long-term adverse effects of inhaled corticosteroids. Allergy. marzo de 1999;54(s49):29-34.30. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 29 de marzo de 2021;n71.31. Zotero | Your personal research assistant [Internet]. [citado 11 de septiembre de 2023]. Disponible en: https://www.zotero.org/32. Covidence [Internet]. [citado 2 de noviembre de 2023]. Covidence - Better systematic review management. Disponible en: https://www.covidence.org/33. WebPlotDigitizer - Extract data from plots, images, and maps [Internet]. [citado 13 de septiembre de 2023]. Disponible en: https://automeris.io/WebPlotDigitizer/34. Sterne JAC, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 28 de agosto de 2019;l4898.35. Page MJ, Sterne JAC, Higgins JPT, Egger M. Investigating and dealing with publication bias and other reporting biases in meta‐analyses of health research: A review. Res Synth Methods. marzo de 2021;12(2):248-59.36. Egger M, Smith GD, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 13 de septiembre de 1997;315(7109):629-34.37. Cornell JE, Mulrow CD, Localio R, Stack CB, Meibohm AR, Guallar E, et al. Random-Effects Meta-analysis of Inconsistent Effects: A Time for Change. Ann Intern Med. 18 de febrero de 2014;160(4):267-70.38. Turner RM, Davey J, Clarke MJ, Thompson SG, Higgins JP. Predicting the extent of heterogeneity in meta-analysis, using empirical data from the Cochrane Database of Systematic Reviews. Int J Epidemiol. junio de 2012;41(3):818-27.39. Rhodes KM, Turner RM, Higgins JPT. Predictive distributions were developed for the extent of heterogeneity in meta-analyses of continuous outcome data. J Clin Epidemiol. enero de 2015;68(1):52-60.40. Salanti G. Indirect and mixed-treatment comparison, network, or multiple-treatments meta-analysis: many names, many benefits, many concerns for the next generation evidence synthesis tool. Res Synth Methods. junio de 2012;3(2):80-97.41. Mills EJ, Thorlund K, Ioannidis JPA. Demystifying trial networks and network meta-analysis. BMJ. 14 de mayo de 2013;346(may14 2):f2914-f2914.42. Veroniki AA, Straus SE, Fyraridis A, Tricco AC. The rank-heat plot is a novel way to present the results from a network meta-analysis including multiple outcomes. J Clin Epidemiol. agosto de 2016;76:193-9.43. Veroniki AA, Vasiliadis HS, Higgins JP, Salanti G. Evaluation of inconsistency in networks of interventions. Int J Epidemiol. 1 de febrero de 2013;42(1):332-45.44. Jackson D, Barrett JK, Rice S, White IR, Higgins JPT. A design‐by‐treatment interaction model for network meta‐analysis with random inconsistency effects. Stat Med. 20 de septiembre de 2014;33(21):3639-54.45. Veroniki AA, Jackson D, Viechtbauer W, Bender R, Bowden J, Knapp G, et al. Methods to estimate the between‐study variance and its uncertainty in meta‐analysis. Res Synth Methods. marzo de 2016;7(1):55-79.46. Balduzzi S, Rücker G, Nikolakopoulou A, Papakonstantinou T, Salanti G, Efthimiou O, et al. netmeta : An R Package for Network Meta-Analysis Using Frequentist Methods. J Stat Softw [Internet]. 2023 [citado 9 de diciembre de 2023];106(2). Disponible en: https://www.jstatsoft.org/v106/i02/47. Allen DB. Do intranasal corticosteroids affect childhood growth? Allergy Eur J Allergy Clin Immunol Suppl. 2000;55(62):15-8.48. Li AR, Zhang K, Reddy PD, Nguyen SA, Miglani A, Fried J, et al. Systematic review of measures of disease severity in rhinitis. Int Forum Allergy Rhinol. septiembre de 2021;11(9):1367-77.49. Schandelmaier S, Briel M, Varadhan R, Schmid CH, Devasenapathy N, Hayward RA, et al. Development of the Instrument to assess the Credibility of Effect Modification Analyses (ICEMAN) in randomized controlled trials and meta-analyses. Can Med Assoc J. 10 de agosto de 2020;192(32):E901-6.50. Puhan MA, Schunemann HJ, Murad MH, Li T, Brignardello-Petersen R, Singh JA, et al. A GRADE Working Group approach for rating the quality of treatment effect estimates from network meta-analysis. BMJ. 24 de septiembre de 2014;349(sep24 5):g5630-g5630.51. Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J, et al. GRADE guidelines: 1. Introduction—GRADE evidence profiles and summary of findings tables. J Clin Epidemiol. abril de 2011;64(4):383-94.52. Guyatt GH, Oxman AD, Kunz R, Woodcock J, Brozek J, Helfand M, et al. GRADE guidelines: 7. Rating the quality of evidence—inconsistency. J Clin Epidemiol. diciembre de 2011;64(12):1294-302.53. Guyatt GH, Oxman AD, Kunz R, Brozek J, Alonso-Coello P, Rind D, et al. GRADE guidelines 6. Rating the quality of evidence—imprecision. J Clin Epidemiol. diciembre de 2011;64(12):1283-93.54. Guyatt GH, Oxman AD, Montori V, Vist G, Kunz R, Brozek J, et al. GRADE guidelines: 5. Rating the quality of evidence—publication bias. J Clin Epidemiol. diciembre de 2011;64(12):1277-82.55. Dias S, Welton NJ, Caldwell DM, Ades AE. Checking consistency in mixed treatment comparison meta‐analysis. Stat Med. 30 de marzo de 2010;29(7-8):932-44.56. Brignardello-Petersen R, Florez ID, Izcovich A, Santesso N, Hazlewood G, Alhazanni W, et al. GRADE approach to drawing conclusions from a network meta-analysis using a minimally contextualised framework. BMJ. 11 de noviembre de 2020;m3900.57. Berger WE, Nayak A, Lanier BQ, Kaiser HB, LaForce C, Darken P, et al. Efficacy and safety of once-daily ciclesonide nasal spray in children with allergic rhinitis. Pediatr Asthma Allergy Immunol. 2008;21(2):73.58. Mak KK, Ku MS, Lu KH, Sun HL, Lue KH. Comparison of mometasone furoate monohydrate (Nasonex) and fluticasone propionate (Flixonase) nasal sprays in the treatment of dust mite-sensitive children with perennial allergic rhinitis. Pediatr Neonatol. 2013;54(4):239-45.59. Indolfi C, Dinardo G, Umano GR, Klain A, Contieri M, Decimo A, et al. Mometasone furoate nasal spray in Italian children with seasonal allergic rhinitis: a comprehensive assessment. Allergol Immunopathol (Madr). 2022;50(5):61-7.60. Zicari AM, Occasi F, Montanari G, Indinnimeo L, De Castro G, Tancredi G, et al. Intranasal budesonide in children affected by persistent allergic rhinitis and its effect on nasal patency and Nasal Obstruction Symptom Evaluation (NOSE) score. Curr Med Res Opin. 2015;31(3):391.61. Gale AE, Solomon E, Tao BS. Intranasal topical flunisolide therapy in children with seasonal allergic rhinitis. Clin Allergy. 1980;10(5):527.62. Lee LA, Sterling R, Maspero J, Clements D, Ellsworth A, Pedersen S. Growth velocity reduced with once-daily fluticasone furoate nasal spray in prepubescent children with perennial allergic rhinitis. J Allergy Clin Immunol Pract. 2014;2(4):421-7.63. Okubo K, Okamasa A, Honma G, Komatsubara M. Safety and efficacy of fluticasone furoate nasal spray in Japanese children 2 to <15 years of age with perennial allergic rhinitis: a multicentre, open-label trial. Allergol Int Off J Jpn Soc Allergol. 2015;64(1):60-5.64. Tripathy I, Levy A, Ratner P, Clements D, Wu W, Philpot E. HPA axis safety of fluticasone furoate nasal spray once daily in children with perennial allergic rhinitis. Pediatr Allergy Immunol Off Publ Eur Soc Pediatr Allergy Immunol. 2009;20(3):287-94.65. GlaxoSmithKline. Study FFR116364, a Double-blind, Placebo-controlled Study of GW685698X in Paediatric Subjects With Perennial Allergic Rhinitis [Internet]. clinicaltrials.gov; 2016. Disponible en: https://clinicaltrials.gov/study/NCT0163013566. Meltzer EO, Lee J, Tripathy I, Lim J, Ellsworth, A, et al. Efficacy and safety of once-daily fluticasone furoate nasal spray in children with seasonal allergic rhinitis treated for 2 wk. Pediatr Allergy Immunol. 2008;67. Maspero JF, Rosenblut A, Finn AJ, Lim J, Wu W, Philpot E. Safety and efficacy of fluticasone furoate in pediatric patients with perennial allergic rhinitis. Otolaryngol--Head Neck Surg Off J Am Acad Otolaryngol-Head Neck Surg. 2008;138(1):30-7.68. Banov CH, Silvers WS, Green AW, van Bavel JH, Winder JA, Feiss G, et al. Placebo-controlled, double-blind study of the efficacy and safety of triamcinolone acetonide aerosol nasal inhaler in pediatric patients with seasonal allergic rhinitis. Clin Ther. 1996;18(2):265.69. Storms WW, Southern DL, Feiss G, Simpson B, Furst JA, Smith JA. Efficacy of triamcinolone acetonide aerosol nasal inhaler in children with perennial allergic rhinitis. Pediatr Asthma Allergy Immunol. 1996;10(2):59.70. Schenkel EJ, Gross G, Jacobson K, Kobayashi R, Settipane G, Savacool AM, et al. Triamcinolone acetonide aqueous nasal inhaler for the treatment of spring grass seasonal allergic rhinitis in children. Pediatr Asthma Allergy Immunol. 1997;11(2):129.71. Weinstein S, Qaqundah P, Georges G, Nayak A. Efficacy and safety of triamcinolone acetonide aqueous nasal spray in children aged 2 to 5 years with perennial allergic rhinitis: a randomized, double-blind, placebo-controlled study with an open-label extension. Ann Allergy Asthma Immunol. 2009;102(4):339.72. Sanofi. A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study Evaluating the Pharmacodynamic Effect of a 6-week Treatment With Triamcinolone Acetonide Aqueous Nasal Spray 110 μg and 220 μg Once Daily on Basal Hypothalamic-Pituitary-Adrenal (HPA) Axis Function in Children [>=2 to < 12 Years of Age] With Allergic Rhinitis (AR). [Internet]. clinicaltrials.gov; 2012 jun [citado 31 de diciembre de 2022]. Report No.: NCT01154153. Disponible en: https://clinicaltrials.gov/study/NCT0115415373. Agertoft L, Wolthers OD, Fuglsang G, Pedersen S. Nasal powder administration of budesonide for seasonal rhinitis in children and adolescents. Pediatr Allergy Immunol Off Publ Eur Soc Pediatr Allergy Immunol. 1993;4(3):152-6.74. Ferrante G, Fasola S, Cilluffo G, Malizia V, Montalbano L, Landi M, et al. Nasal budesonide efficacy for nasal nitric oxide and nasal obstruction in rhinitis. Pediatr Allergy Immunol. 2017;28(4):393-7.75. Fokkens WJ, Cserhati E, dos Santos JML, Praca F, van Zanten M, Schade A, et al. Budesonide aqueous nasal spray is an effective treatment in children with perennial allergic rhinitis, with an onset of action within 12 hours. Ann Allergy Asthma Immunol Off Publ Am Coll Allergy Asthma Immunol. 2002;89(3):279-84.76. Ngamphaiboon J, Thepchatri A, Chatchatee P, Chumdermpadetsuk S. Fluticasone propionate aqueous nasal spray treatment for perennial allergic rhinitis in children. Ann Allergy Asthma Immunol Off Publ Am Coll Allergy Asthma Immunol. 1997;78(5):479-84.77. Fluticasone P Collab Work Group. Treatment of seasonal allergic rhinitis with once-daily intranasal fluticasone propionate therapy in children. Fluticasone Propionate Collaborative Pediatric Working Group. J Pediatr. 1994;125(4):628-34.78. Grossman J, Banov C, Bronsky EA, Nathan RA, Pearlman D, Winder JA, et al. Fluticasone propionate aqueous nasal spray is safe and effective for children with seasonal allergic rhinitis. Pediatrics. 1993;92(4):594-9.79. Munk ZM, Pearlman D, Graft D, Green A, Hampel F, Pleskow W, et al. Intranasal fluticasone propionate is effective and well-tolerated in adolescents with seasonal allergic rhinitis. Pediatr Asthma Allergy Immunol. 1994;8(1):39.80. Baena-Cagnani CE, Patel P. Efficacy and long-term safety of mometasone furoate nasal spray in children with perennial allergic rhinitis. Curr Med Res Opin. 2010;26(9):2047.81. Organon and Co. Multicenter, Double-blind, Randomized, Placebo-controlled Study of Mometasone Furoate Nasal Spray in Pediatric Subjects With Perennial Allergic Rhinitis (Protocol No.P06332) [Internet]. clinicaltrials.gov; 2024 may [citado 8 de diciembre de 2024]. Report No.: NCT01135134. Disponible en: https://clinicaltrials.gov/study/NCT0113513482. Berger WE, Jacobs RL, Amar NJ, Tantry SK, Li J, Small CJ. Efficacy and safety of beclomethasone dipropionate nasal aerosol in children with perennial allergic rhinitis. Ann Allergy Asthma Immunol. 2015;115(2):130-6.83. Lin MT, Collins-Williams C. Intranasal beclomethasone dipropionate for perennial allergic rhinitis. Can Med Assoc J. 1977;116(8):895-6.84. Sarsfield JK, Thomson GE. Flunisolide nasal spray for perennial rhinitis in children. Br Med J. 1979;2(6182):95-7.85. Meltzer EO, Berger WE, Berkowitz RB, Bronsky EA, Dvorin DJ, Finn AF, et al. A dose-ranging study of mometasone furoate aqueous nasal spray in children with seasonal allergic rhinitis. J Allergy Clin Immunol. 1999;104(1):107.86. Organon and Co. Dose-Ranging Study of Mometasone Furoate Nasal Spray (SCH 32088) in the Treatment of Children (Ages 6-11) With Seasonal Allergic Rhinitis (Protocol C95-161) [Internet]. clinicaltrials.gov; 2022. Disponible en: https://clinicaltrials.gov/study/NCT0387977287. Sumitomo Pharma America Inc. A 12-Week Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Safety and Efficacy Study of Ciclesonide Nasal Aerosol in Subjects 6-11 Years With Perennial Allergic Rhinitis [Internet]. clinicaltrials.gov; 2014. Disponible en: https://clinicaltrials.gov/study/NCT0145154188. Skoner DP, Gentile D, Angelini B, Kane R, Birdsall D, Banerji D. The effects of intranasal triamcinolone acetonide and intranasal fluticasone propionate on short-term bone growth and HPA axis in children with allergic rhinitis. Ann Allergy Asthma Immunol. 2003;90(1):56.89. Sanofi. A Randomized, Multicenter, Double-blind, Placebo-controlled, Parallel Group Study of the 12 Month Effect of Treatment With Once Daily Triamcinolone Acetonide (NASACORT® AQ Nasal Spray 110 μg) on the Growth Velocity of Children, 3 to 9 Years of Age, With Perennial Allergic Rhinitis (PAR) [Internet]. clinicaltrials.gov; 2012 ago [citado 31 de diciembre de 2022]. Report No.: NCT00449072. Disponible en: https://clinicaltrials.gov/study/NCT0044907290. Georges G, Kim KT, Ratner P, Segall N, Qiu C. Effect of intranasal triamcinolone acetonide on basal hypothalamic-pituitary-adrenal axis function in children with allergic rhinitis. Allergy Asthma Proc. 2014;35(2):163-70.91. EudraCT Number 2014-004645-27 - Clinical trial results - EU Clinical Trials Register [Internet]. [citado 10 de diciembre de 2024]. Disponible en: https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-004645-27/results92. Boner AL, Sette L. Rhinitis in children: efficacy and safety of a new intranasal corticosteroid. Eur Respir Rev. 1994;4(20):271.93. Galant SP, Melamed IR, Nayak AS, Blake KV, Prillaman BA, Reed KD, et al. Lack of effect of fluticasone propionate aqueous nasal spray on the hypothalamic-pituitary-adrenal axis in 2- and 3-year-old patients. Pediatrics. 2003;112(1 Pt 1):96-100.94. Allen DB, Meltzer EO, Lemanske RF, Philpot EE, Faris MA, Kral KM, et al. No growth suppression in children treated with the maximum recommended dose of fluticasone propionate aqueous nasal spray for one year. Allergy Asthma Proc. 2002;23(6):407.95. Hampel FC, Nayak NA, Segall N, Small CJ, Li J, Tantry SK. No hypothalamic-pituitary-adrenal function effect with beclomethasone dipropionate nasal aerosol, based on 24-hour serum cortisol in pediatric allergic rhinitis. Ann Allergy Asthma Immunol. 2015;115(2):137-42.96. Skoner DP, Rachelefsky GS, Meltzer EO, Chervinsky P, Morris RM, Seltzer JM, et al. Detection of growth suppression in children during treatment with intranasal beclomethasone dipropionate. Pediatrics. 2000;105(2):E23.97. Storms WW, Segall N, Mansfield LE, Amar NJ, Kelley L, Ding Y, et al. Efficacy and safety of beclomethasone dipropionate nasal aerosol in pediatric patients with seasonal allergic rhinitis. Ann Allergy Asthma Immunol. 2013;111(5):408-414.e1.98. Berger WE, Jacobs RL, Amar NJ, Tantry SK, Li J, Small CJ. Efficacy and safety of beclomethasone dipropionate nasal aerosol in children with perennial allergic rhinitis. Ann Allergy Asthma Immunol Off Publ Am Coll Allergy Asthma Immunol. agosto de 2015;115(2):130-6.99. Organon and Co. Efficacy and Safety of Mometasone Furoate Aqueous Nasal Spray vs Placebo and Flonase® (Fluticasone Propionate) in Seasonal Allergic Rhinitis Patients (I94-001) [Internet]. clinicaltrials.gov; 2022 feb [citado 31 de diciembre de 2022]. Report No.: NCT03882047. Disponible en: https://clinicaltrials.gov/study/NCT03882047100. Kim KT, Rabinovitch N, Uryniak T, Simpson B, O’Dowd L, Casty F. Effect of budesonide aqueous nasal spray on hypothalamic-pituitary-adrenal axis function in children with allergic rhinitis. Ann Allergy Asthma Immunol Off Publ Am Coll Allergy Asthma Immunol. 2004;93(1):61-7.101. Murphy K, Uryniak T, Simpson B, O’Dowd L. Growth velocity in children with perennial allergic rhinitis treated with budesonide aqueous nasal spray. Ann Allergy Asthma Immunol Off Publ Am Coll Allergy Asthma Immunol. 2006;96(5):723-30.102. Agertoft L, Pedersen S. Short-term lower leg growth rate in children with rhinitis treated with intranasal mometasone furoate and budesonide. J Allergy Clin Immunol. 1999;104(5):948.103. Wolthers OD, Jørgensen BA, Pedersen S. A double-blind, placebo-controlled study of the effect of intranasal budesonide in the treatment of children with seasonal rhinitis. Acta Paediatr. noviembre de 1992;81(11):902-6.104. Okubo K, Okamasa A, Honma G, Komatsubara M. Efficacy and safety of fluticasone furoate nasal spray in Japanese children with perennial allergic rhinitis: a multicentre, randomized, double-blind, placebo-controlled trial. Allergol Int Off J Jpn Soc Allergol. 2014;63(4):543-51.105. Maspero JF, Rosenblut A, Finn A Jr, Lim J, Wu W, Faris M, et al. Once daily fluticasone furoate nasal spray (FF) is safe and effective in long term treatment of perennial allergic rhinitis (PAR) in children ages 2 to 11 years USAN approved name. J Allergy Clin Immunol. 2007;119(1 Suppl):S304.106. Zhang Y, Wei P, Chen B, Li X, Luo X, Chen X, et al. Intranasal fluticasone furoate in pediatric allergic rhinitis: randomized controlled study. Pediatr Res. 2021;89(7):1832.107. Cutler DL, Banfield C, Affrime MB. Safety of mometasone furoate nasal spray in children with allergic rhinitis as young as 2 years of age: a randomized controlled trial. Pediatr Asthma Allergy Immunol. 2006;19(3):146.108. Schenkel EJ, Skoner DP, Bronsky EA, Miller SD, Pearlman DS, Rooklin A, et al. Absence of growth retardation in children with perennial allergic rhinitis after one year of treatment with mometasone furoate aqueous nasal spray. Pediatrics. 2000;105(2):E22.109. Meltzer EO, Berger WE, Berkowitz RB, Bronsky EA, Dvorin DJ, Finn AF, et al. A dose-ranging study of mometasone furoate aqueous nasal spray in children with seasonal allergic rhinitis. J Allergy Clin Immunol. 1999;104(1):107.110. Ratner PH, Meltzer EO, Teper A. Mometasone furoate nasal spray is safe and effective for 1-year treatment of children with perennial allergic rhinitis. Int J Pediatr Otorhinolaryngol. 2009;73(5):651-7.111. Skoner DP, Berger WE, Gawchik SM, Akbary A, Qiu C. Intranasal triamcinolone and growth velocity. Pediatrics. 2015;135(2):e348.112. Agertoft L, Pedersen S. Short-term lower leg growth rate in children with rhinitis treated with intranasal mometasone furoate and budesonide. J Allergy Clin Immunol. 1999;104(5):948.113. Wolthers OD, Pedersen S. Knemometric assessment of systemic activity of once daily intranasal dry-powder budesonide in children. 1994;49(2):96.114. Gradman J, Caldwell MF, Wolthers OD. A 2-week, crossover study to investigate the effect of fluticasone furoate nasal spray on short-term growth in children with allergic rhinitis. Clin Ther. 2007;29(8):1738-47.115. Barnes ML, Vaidyanathan S, Williamson PA, Lipworth BJ. The minimal clinically important difference in allergic rhinitis. Clin Exp Allergy. febrero de 2010;40(2):242-50.116. Cohen J. The earth is round (p < .05). APA PsycArticles J Artic. 1994;49(12):997-1003.117. Kırıs M, Muderris T, Celebi S, Cankaya H, Bercin S. Changes in serum IGF-1 and IGFBP-3 levels and growth in children following adenoidectomy, tonsillectomy or adenotonsillectomy. Int J Pediatr Otorhinolaryngol. mayo de 2010;74(5):528-31.118. Li Y, Xiong J, Zhang Z, Liao K, Zhou X, Li J, et al. Efficacy and safety of various corticosteroids in the treatment of children with allergic rhinitis: A systematic review and network meta‐analysis. J Evid-Based Med. septiembre de 2024;17(3):626-42.119. Sousa‐Pinto B, Vieira RJ, Bognanni A, Gil‐Mata S, Ferreira‐da‐Silva R, Ferreira A, et al. Efficacy and safety of intranasal medications for allergic rhinitis: Network meta‐analysis. Allergy. 16 de noviembre de 2024;all.16384.120. Lei R, Shen Q, Yang B, Hou T, Liu H, Luo X, et al. Core Outcome Sets in Child Health: A Systematic Review. JAMA Pediatr. 1 de noviembre de 2022;176(11):1131Rinitis alérgicaRhinitis, AllergicPoblación pediátricaEsteroides nasales tópicoshttps://id.nlm.nih.gov/mesh/D065631ODS 3: Salud y bienestar. Garantizar una vida sana y promover el bienestar de todos a todas las edadesPublicationORIGINALOsornoSantiago_2025_Esteroides_Niños_Rinitis.pdfOsornoSantiago_2025_Esteroides_Niños_Rinitis.pdfTesis de maestríaapplication/pdf1153506https://bibliotecadigital.udea.edu.co/bitstreams/d69baa8d-8bd3-405f-9db9-1a4eeb43bd4e/download7e906757aab883ed3b6c8f5d8a3112f8MD56trueAnonymousREADOsornoSantiago_2025_SupplementalMaterialTNS.docxOsornoSantiago_2025_SupplementalMaterialTNS.docxapplication/vnd.openxmlformats-officedocument.wordprocessingml.document1380111https://bibliotecadigital.udea.edu.co/bitstreams/cafcc0b0-c894-4bde-ac9c-cf98a8c292c1/download943840d5e8d6889d208ac236bea1b48eMD52falseAnonymousREADLICENSElicense.txtlicense.txttext/plain; charset=utf-814837https://bibliotecadigital.udea.edu.co/bitstreams/8f39dbbe-f3de-4dfc-984c-f47aeaaef26a/downloadb76e7a76e24cf2f94b3ce0ae5ed275d0MD55falseAnonymousREADCC-LICENSElicense_rdflicense_rdfapplication/rdf+xml; charset=utf-81160https://bibliotecadigital.udea.edu.co/bitstreams/2fe6045f-d32e-4eae-a7bf-b5521d18c169/download5643bfd9bcf29d560eeec56d584edaa9MD58falseAnonymousREADTEXTOsornoSantiago_2025_Esteroides_Niños_Rinitis.pdf.txtOsornoSantiago_2025_Esteroides_Niños_Rinitis.pdf.txtExtracted texttext/plain74412https://bibliotecadigital.udea.edu.co/bitstreams/36ca478d-e523-41b0-bef6-475b4812d10b/downloadd32dae1c90884c476680de7b1bc8cfa5MD59falseAnonymousREADOsornoSantiago_2025_SupplementalMaterialTNS.docx.txtOsornoSantiago_2025_SupplementalMaterialTNS.docx.txtExtracted texttext/plain65323https://bibliotecadigital.udea.edu.co/bitstreams/9b67e894-4c7e-45e1-a4f9-b10759ca1fe4/downloadfacfa2b28665af6fdd2a661db99edffeMD511falseAnonymousREADTHUMBNAILOsornoSantiago_2025_Esteroides_Niños_Rinitis.pdf.jpgOsornoSantiago_2025_Esteroides_Niños_Rinitis.pdf.jpgGenerated Thumbnailimage/jpeg7183https://bibliotecadigital.udea.edu.co/bitstreams/0f7a1fa9-58e9-4173-b273-a9d2eaaa6602/download12dffd27729aa62fe1d1ca865c7ce208MD510falseAnonymousREAD10495/47792oai:bibliotecadigital.udea.edu.co:10495/477922025-10-17 04:02:19.827http://creativecommons.org/licenses/by-nc-sa/4.0/Attribution-NonCommercial-ShareAlike 4.0 Internationalopen.accesshttps://bibliotecadigital.udea.edu.coRepositorio Institucional de la Universidad de Antioquiaaplicacionbibliotecadigitalbiblioteca@udea.edu.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

Publicaciones similares